JP Morgan maintains Becton Dickinson at Neutral, raises price target to $202 from $170

JP Morgan kept Becton Dickinson at Neutral but raised its price target to $202 from $170, suggesting a 4.7% downside from the Nov 6 close of $211.88. Recent analyst targets range from $200 to $242.

Original reporting
Published Nov 7, 2026, 2:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 2:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Becton Dickinson at Neutral, raises price target to $202 from $170 — source image
Decision brief

The 30-second read

$BDXNeutralMed
01

Why it matters

The upgrade may affect short-term trading as the stock trades above the new target, possibly prompting profit-taking.

02

Market read

Analyst price target changes can move investor sentiment and short-term price action for the stock.

03

What to watch

Potential supply chain constraints or regulatory risks not addressed in the note.

Relevance 6/10Novelty 6/10Timing: immediate today

Background

JP Morgan's analyst note updates the price target for Becton Dickinson, reflecting a revised outlook.

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

JP Morgan raised its price target on Becton Dickinson to $202 from $170.

Expected impact

potential downside as the market may price in the higher target while the stock trades above it

Evidence & confidence

The target increase signals confidence, yet the current price exceeds the new target, likely prompting short-term pressure.

Market effects

May influence sentiment in the medical devices sector as analysts adjust expectations.

Limited to US markets where BDX is listed.

Low global impact beyond sector peers.

Counterpoint

The price target raise could be premature if recent earnings missed expectations.

Key entities

  • Becton Dickinson

    Medical device manufacturer (ticker BDX).

  • JP Morgan

    Investment bank providing the price target revision.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.